Sequence
44 amino acids
Origin
Synthetic GHRH analogue
Research Dose
Clinical dose is 2mg subcutaneous daily. Research protocols often mirror this. Some use lower doses (1mg) or every-other-day protocols.
Category
Growth Hormone
How It Works
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification that improves stability. It stimulates the pituitary to release growth hormone naturally while preserving physiological feedback. FDA-approved as Egrifta for HIV-associated lipodystrophy, it specifically reduces visceral adipose tissue.
Key Benefits
FDA-approved for lipodystrophy
Reduces visceral (belly) fat
Stimulates natural GH release
May improve cognitive function
Research Highlights
FDA-approved as Egrifta for HIV-associated lipodystrophy
Reduces visceral fat by 15-18% in clinical trials
Does not significantly affect subcutaneous fat
COGITO trial showed improved cognitive function in healthy older adults
Maintains IGF-1 within physiological range
Available Forms
- Lyophilized powder for injection
Legal Status
Tesamorelin is FDA-approved as Egrifta (prescription required). Research-grade tesamorelin available from peptide suppliers.
Research & Education Only — The information on this page is for research and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any decisions.